Skip to content
Back to Investors
XTX Ventures

XTX Ventures

Venture Capital

XTX Ventures is the venture capital arm of XTX Markets, investing in early-stage companies where AI and machine learning are a core technology.

Portfolio

14

companies

Investment by month

By category

  • AI/ML£114M
  • FinTech£27.7M
  • Uncategorised£20.5M
  • EdTech£1.7M
  • BioTech£889K

By location

  • London£113M
  • Cambridge£21.8M
  • Washington£20.5M
  • Nottingham£3.4M
  • Newcastle upon Tyne£2.5M
  • Other£4.2M

Portfolio companies

BA

BlueSkeye AI

BlueSkeye AI builds face and voice analysis technology to assess mood and mental wellbeing.

Cognitive Credit

Cognitive Credit

Cognitive Credit builds data and analytics software for corporate credit markets.

G

Graide

Graide offers an AI-powered assessment platform that helps educators mark student assignments.

I

InvenireX

InvenireX builds a DNA nanotechnology platform to detect disease at early biological stages.

Logically

Logically

Logically uses advanced artificial intelligence to tackle online mis- and disinformation at scale.

Lucida Medical

Lucida Medical

Lucida Medical develops artificial intelligence software to accelerate and improve cancer diagnostics from MRI scans.

View all 14 companies

Team

EH

Ekaterina Holt

Head of XTX Ventures

OS

Oliver Scott

Global Head of Treasury at XTX Markets

GP

Gabriele Papievyte

Head of Ventures

Gabriele heads ventures at XTX Markets and advises the Department for Science, Innovation and Technology. She also holds investor and board roles across several technology companies.

LinkedIn

Recent investments

$35.0M

The funding supports the development of optical networking technology designed to remove electronic switches from data centre cores.

"A year ago, we were proving the physics; today, we’re proving the business. Our collaboration with AMD has moved from concept to deployment to a system an order of magnitude larger, and the data proves this is already driving performance increases at pace,"
— James Regan
Pre-Seed
$1.2M

The pre_seed round was led by 55 North to support platform expansion and upcoming pharmaceutical pilots.

"Early on in our research, we started looking at ways to get the most out of the quantum devices we had access to. That’s where some of these ideas started to form, which have eventually become what we’re now calling quantum compression,"
— Timothy Weaving
£8.7M

The funding round included participation from XTX Ventures and Macmillan Cancer Support to accelerate deployment and expand diagnostics.

"Cancer imaging volumes are rising rapidly but reporting capacity is not keeping pace. Our goal is to give clinicians faster, more confident decisions while reducing unnecessary interventions for patients. With our deep focus on prostate cancer and strong clinical validation across NHS pathways, we’re showing how AI can deliver earlier and more accurate diagnoses. In the NHS, few Trusts can confirm or rule out cancer within 28 days, and some patients can wait two months or longer. Lucida Medical is ideally placed to reduce this burden, and this funding will allow us to do that faster."
— Antony Rix, Co-founder and CEO
Seed
£4.0M

The seed round was led by XTX Ventures to expand team capacity and boost production capabilities.

"Across the different chemical industries everyone wants to be more efficient and produce the compounds society needs quicker, despite the challenges industry faces. We are helping pharmaceutical, agrochemical, and specialty chemical companies do just that."
— Linden Schrecker, CEO